Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

CryptoTechFlowChinese, translatedFiled 5 days ago

BeiGene plans to invest USD 19.5 million to participate in Bravera's Series A financing.

Original headline百济神州拟出资 1950 万美元参与 Bravera A 轮融资

Open the sourceReported by TechFlow, techflowpost.com, 16 November 2026, by TechFlowDaily

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

BeiGene’s wholly owned subsidiary BeiGene Switzerland plans to invest $19.5 million in cash in Bravera Bio’s Series A round alongside affiliate Baker Bros entities and other investors, while converting a $500,000 SAFE interest into Series A preferred shares. Upon completion, BeiGene Switzerland will hold 9.477% of Bravera. The transaction is a related-party deal but not a major asset restructuring, so it does not require board or shareholder approval. The move ties the oncology-focused biotech to Bravera’s early-stage pipeline and marks a modest but strategic deployment of capital through an affiliated investment structure.

Muhabbit's AI wrote this summary in its own words from TechFlow's report and translated it from Chinese. It can get details wrong, so check the source.

Named in this story

百济神州, Bravera Bio, 百济瑞士, Baker Bros